Citations

Clear

959 citation(s) found for "Service, F J".

FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial
Groothoff, Jaap W. , Michael, Mini , Shasha‐Lavsky, Hadas , Frishberg, Yaacov, Šimková, Eva, Sellier‐Leclerc, Anne‐Laure , Devresse, Arnaud , Mourani, Chebl, Saqan, Rola , Singer, Richard, Willey, Richard E., Habtemariam, Bahru, Bhan, Ishir , Gansner, John M. , Magen, Daniella , Singer, Richard , Lieske, John C. , Guebre‐Egziabher, Fitsum , Bakkaloglu, Sevcan Azime , Singer, Richard, Willey, Richard

Mayo Clinic

Nephrology Dialysis Transplantation | May 5, 2022 | Volume: 37 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfac112.002 Get It

Abstract BACKGROUND AND AIMS Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder characterised by hepatic oxalate overproduction that leads to progressive kidney disease. As kidney function declines, oxalate elimination is compromised and plasma oxalate (POx) increases, leading to systemic oxalosis. In chronic kidney disease (CKD) stages 3b–5, elevated POx is directly related to the pathophysiology of oxalosis, and reduction of POx is a relevant clinical trial endpoint. Lumasiran, an RNA interference therapeutic designed to reduce hepatic oxalate production, is indicated for the treatment of PH1 in all age groups. Data from the ILLUMINATE-C trial (EudraCT: 2019–0 013 346-17) demonstrated substantial reductions in POx and acceptable safety in patients with PH1 with impaired kidney function, including patients on haemodialysis (HD), who received lumasiran for 6 months. In Cohorts A (no HD) and B (on HD), respectively, lumasiran led to 33.33% [95% confidence interval (95% CI): −15.16 to 81.82] and 42.43% (95% CI: 34.15–50.71) least-squares (LS) mean reductions in POx from baseline to Month 6 (the primary endpoint). Here, we present METHOD ILLUMINATE-C is an ongoing Phase 3, single-arm study with two cohorts, Cohort A (N = 6; no HD at study start) and Cohort B (N = 15; on HD). The 6-month primary analysis period is followed by an extension period (EP) of up to 54 months. Key inclusion criteria include genetically confirmed PH1, eGFR ≤ 45 mL/min/1.73 m2 and POx ≥ 20 μmol/L. Patients received weight-based dosing of subcutaneous lumasiran. Outcomes of interest for the current analysis included assessments of cardiac oxalosis using echocardiography, medullary nephrocalcinosis by kidney ultrasound, kidney stone events and burdensome symptoms of PH1. RESULTS All 21 patients [43% female; 76% white; median age 8 (range 0–59) years] completed the 6-month primary analysis period. Among patients with abnormal left ventricular ejection fraction (LVEF; abnormal defined as LVEF < 55%) at baseline, 1/1 patient in Cohort A and 2/4 patients in Cohort B showed ≥ 5% improvement at Month 6. Among patients with abnormal global longitudinal strain (GLS, a measure of LV contractility more sensitive than LVEF for predicting outcomes; abnormal defined as |GLS| <15%) at baseline, 1/1 patient in Cohort A and 3/3 patients in Cohort B showed ≥ 2% improvement at Month 6. In Cohort A, 5/6 patients had nephrocalcinosis at baseline, 2 remained stable, none worsened, and 3 improved (2 unilateral and 1 bilateral improvement) at Month 6. In Cohort A, 1 patient did not have nephrocalcinosis at baseline and had bilateral worsening at Month 6. In Cohort B, 2/11 patients had nephrocalcinosis at baseline; both improved (1 unilateral and 1 bilateral improvement). In Cohort A, the rate of kidney stone events per person-year was 3.20 (95% CI: 1.96–5.22) in the 12 months prior to consent and 1.48 (95% CI: 0.55–3.92) during the first 6 months of lumasiran treatment. For patients in both cohorts, the most burdensome symptoms at baseline, including fatigue, nausea/decreased appetite, bone pain and decreased mobility, improved or remained stable at Month 6; none of the symptoms worsened. CONCLUSION Lumasiran treatment resulted in substantial reductions in POx in patients of all ages with PH1 and advanced kidney disease. The observations regarding cardiac measures that reflect systemic oxalosis, together with the kidney stone event and nephrocalcinosis results, are consistent with mobilisation of oxalate from systemic stores. Data on these long-term outcomes will continue to be collected and further evaluated in the EP. These results, along with previous reports from ILLUMINATE-A and ILLUMINATE-B, provide evidence supporting the effectiveness of lumasiran across the full spectrum of patients affected by PH1.
Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions
Wirrell, Elaine , Nabbout, Rima , Scheffer, Ingrid E. , Alsaadi, Taoufik , Bogacz, Alicia, French, Jacqueline A. , Hirsch, Édouard , Jain, Satish, Kaneko, Sunao, Riney, Kate , Snead, O. Carter , Somerville, Ernest , Specchio, Nicola , Zuberi, Sameer M. , Balestrini, Simona , Wiebe, Samuel , Cross, J. Helen , Perucca, Emilio , Wirrell, Elaine C , Samia, Pauline , Somerville, Ernest , Specchio, Nicola , Trinka, Eugen , Balestrini, Simona , Wiebe, Samuel , Cross, Helen J , Perucca, Emilio , Moshé, Solomon L , Hirsch, Edouard , French, Jacqueline , Scheffer, Ingrid E , Zuberi, Sameer M , Jain, Satish, Samia, Pauline , Trinka, Eugen , Moshé, Solomon L. , Tinuper, Paolo

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1333-1348

10.1111/epi.17237 | PMID 35503715 Get It

AbstractEpilepsy syndromes have been recognized for >50 years, as distinct electroclinical phenotypes with therapeutic and prognostic implications. Nonetheless, no formally accepted International League Against Epilepsy (ILAE) classification of epilepsy syndromes has existed. The ILAE Task Force on Nosology and Definitions was established to reach consensus regarding which entities fulfilled criteria for an epilepsy syndrome and to provide definitions for each syndrome. We defined an epilepsy syndrome as “a characteristic cluster of clinical and electroencephalographic features, often supported by specific etiological findings (structural, genetic, metabolic, immune, and infectious).” The diagnosis of a syndrome in an individual with epilepsy frequently carries prognostic and treatment implications. Syndromes often have age‐dependent presentations and a range of specific comorbidities. This paper describes the guiding principles and process for syndrome identification in both children and adults, and the template of clinical data included for each syndrome. We divided syndromes into typical age at onset, and further characterized them based on seizure and epilepsy types and association with developmental and/or epileptic encephalopathy or progressive neurological deterioration. Definitions for each specific syndrome are contained within the corresponding position papers.
ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions
Zuberi, Sameer M. , Wirrell, Elaine , Yozawitz, Elissa , Wilmshurst, Jo M. , Specchio, Nicola , Riney, Kate , Pressler, Ronit , Auvin, Stéphane , Samia, Pauline , Hirsch, Édouard , Galicchio, Santiago , Triki, Chahnez , Snead, O. Carter , Wiebe, Samuel , Cross, J. Helen , Scheffer, Ingrid E. , Perucca, Emilio , Nabbout, Rima , Scheffer, Ingrid E , Perucca, Emilio , Moshé, Solomon L , Nabbout, Rima , Wilmshurst, Jo M , Wirrell, Elaine C , Auvin, Stéphane , Yozawitz, Elissa G , Hirsch, Edouard , Cross, Helen J , Samia, Pauline , Specchio, Nicola , Zuberi, Sameer M , Triki, Chahnez , Wiebe, Samuel , Tinuper, Paolo , Moshé, Solomon L.

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1349-1397

10.1111/epi.17239 | PMID 35503712 Get It

Abstract The International League Against Epilepsy (ILAE) Task Force on Nosology and Definitions proposes a classification and definition of epilepsy syndromes in the neonate and infant with seizure onset up to 2 years of age. The incidence of epilepsy is high in this age group and epilepsy is frequently associated with significant comorbidities and mortality. The licensing of syndrome specific antiseizure medications following randomized controlled trials and the development of precision, gene‐related therapies are two of the drivers defining the electroclinical phenotypes of syndromes with onset in infancy. The principal aim of this proposal, consistent with the 2017 ILAE Classification of the Epilepsies, is to support epilepsy diagnosis and emphasize the importance of classifying epilepsy in an individual both by syndrome and etiology. For each syndrome, we report epidemiology, clinical course, seizure types, electroencephalography (EEG), neuroimaging, genetics, and differential diagnosis. Syndromes are separated into self‐limited syndromes, where there is likely to be spontaneous remission and developmental and epileptic encephalopathies , diseases where there is developmental impairment related to both the underlying etiology independent of epileptiform activity and the epileptic encephalopathy. The emerging class of etiology‐specific epilepsy syndromes, where there is a specific etiology for the epilepsy that is associated with a clearly defined, relatively uniform, and distinct clinical phenotype in most affected individuals as well as consistent EEG, neuroimaging, and/or genetic correlates, is presented. The number of etiology‐defined syndromes will continue to increase, and these newly described syndromes will in time be incorporated into this classification. The tables summarize mandatory features, cautionary alerts, and exclusionary features for the common syndromes. Guidance is given on the criteria for syndrome diagnosis in resource‐limited regions where laboratory confirmation, including EEG, MRI, and genetic testing, might not be available.
International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions
Specchio, Nicola , Wirrell, Elaine , Scheffer, Ingrid E. , Nabbout, Rima , Riney, Kate , Samia, Pauline , Guerreiro, Marilisa M. , Gwer, Sam, Zuberi, Sameer M. , Wilmshurst, Jo M. , Yozawitz, Elissa , Pressler, Ronit , Wiebe, Samuel , Cross, J. Helen , Perucca, Emilio , Wirrell, Elaine C , Hirsch, Edouard , Wiebe, Samuel , Cross, Helen J , Perucca, Emilio , Moshé, Solomon L , Auvin, Stéphane , Wilmshurst, Jo M , Yozawitz, Elissa G , Samia, Pauline , Scheffer, Ingrid E , Specchio, Nicola , Zuberi, Sameer M , Gwer, Samson , Hirsch, Édouard , Moshé, Solomon L. , Tinuper, Paolo , Auvin, Stéphane

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1398-1442

10.1111/epi.17241 | PMID 35503717 Get It

Abstract The 2017 International League Against Epilepsy classification has defined a three‐tier system with epilepsy syndrome identification at the third level. Although a syndrome cannot be determined in all children with epilepsy, identification of a specific syndrome provides guidance on management and prognosis. In this paper, we describe the childhood onset epilepsy syndromes, most of which have both mandatory seizure type(s) and interictal electroencephalographic (EEG) features. Based on the 2017 Classification of Seizures and Epilepsies, some syndrome names have been updated using terms directly describing the seizure semiology. Epilepsy syndromes beginning in childhood have been divided into three categories: (1) self‐limited focal epilepsies, comprising four syndromes: self‐limited epilepsy with centrotemporal spikes, self‐limited epilepsy with autonomic seizures, childhood occipital visual epilepsy, and photosensitive occipital lobe epilepsy; (2) generalized epilepsies, comprising three syndromes: childhood absence epilepsy, epilepsy with myoclonic absence, and epilepsy with eyelid myoclonia; and (3) developmental and/or epileptic encephalopathies, comprising five syndromes: epilepsy with myoclonic–atonic seizures, Lennox–Gastaut syndrome, developmental and/or epileptic encephalopathy with spike‐and‐wave activation in sleep, hemiconvulsion–hemiplegia–epilepsy syndrome, and febrile infection‐related epilepsy syndrome. We define each, highlighting the mandatory seizure(s), EEG features, phenotypic variations, and findings from key investigations.
Disparities in Influenza Vaccine Coverage in High-Risk Population, 2010-2020
Felzer, Jamie , JUHN, Y, Wi, C.I., Jacobson, R.M., LeMahieu, Allison , Rutten, Lila J. Finney , Kennedy, Cassie C.

Mayo Clinic

D102. TOPICS IN BEHAVIORAL SCIENCE AND HEALTH SERVICE RESEARCH | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5372-A5372

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5372 Get It

Real-World Medication Adherence Trajectories of Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
Epstein, A.J., Nunag, D., Olson, A.L. , Nili, Mona , Borah, Bijan J.

Mayo Clinic

D102. TOPICS IN BEHAVIORAL SCIENCE AND HEALTH SERVICE RESEARCH | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5358-A5358

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5358 Get It

Patient and Caregiver-Derived Health Service Improvements for Better Critical Care Recovery
Haines, K.J., Leggett, Nina , Hibbert, Elizabeth , Hall, Tarli, Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Harris, Wendy, Hope, Aluko A. , Jackson, J.C., Johnson, Amanda M. , Kloos, Janet A. , Korzick, Karen , MacTavish, Pamela , Montgomery-Yates, Ashley , Slack, Andrew, Still, M. , Netzer, Giora, Hopkins, RO, Sevin, Carla M. , Boehm, Leanne M. , Eaton, Tammy L. , Meyer, Joel , Quasim, Tara , Wade, Dorothy , Mikkelsen, Mark E. , Iwashyna, Theodore J. , McPeake, Joanne

Mayo Clinic

C94. THE ROAD TO RECOVERY TAKES MANY PATHS: OUTCOMES AFTER CRITICAL ILLNESS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4787-A4787

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4787 Get It

Service Learning on the U.S./Mexico Border: Transforming Student Paradigms
Lohr, Abby M. , Iglesias, Charisse S., Ingram, Maia , Valdez, Luis , Zapien, Jill Guernsey de , Rosales, Cecilia , Mantina, Namoonga M. , Valdez, Elizabeth Salerno

Mayo Clinic

Pedagogy in Health Promotion | April 29, 2022 | Volume: 8 | Issue: 3 | Pages: 207-215

10.1177/23733799221085250 Get It

The purpose of our evaluation is to provide an example of how public health schools can use service-learning courses to teach students about health equity. By ensuring that the future workforce has a comprehensive understanding of regions such as the U.S./Mexico border, students will be better equipped to provide public health services. Specifically, our objectives were to (1) understand how student perceptions of the border evolve during the 1-week Border Health Service-Learning Institute (BHSLI) course and (2) understand how the service-learning experience impacted students’ proposed personal and professional goals. Using BHSLI student journals collected over 9 years, we conducted a qualitative investigation to evaluate students’ experiences of the service-learning course. Our findings suggest that BHSLI offered opportunities for advancing dialogue about health equity. Because BHSLI is immersive, it showed students a reality that they would not normally encounter. In reflecting on these new experiences, students were not only encouraged to question systems and policies but also made accountable to act upon the insights they gained. We found that BHSLI was a space for critical consciousness building, for shifting paradigms. Students learned how to intervene in real time to make change around public health issues. Service learning could be a practice-based solution to help public health students learn about health equity, especially in historically marginalized regions such as the U.S./Mexico border.
Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3
García‐Moreno, Héctor , Prudencio, Mercedes , Thomas‐Black, Gilbert , Solanky, Nita , Jansen‐West, Karen , Al‐Shaikh, Rana Hanna , Heslegrave, Amanda , Zetterberg, Henrik , Santana, Magda M. , Almeida, Luís Pereira de , Vasconcelos‐Ferreira, Ana , Infante, Jon , Faber, Jennifer , Klockgether, Thomas , Reetz, Kathrin , Raposo, Mafalda , Ferreira, Ana F. , Lima, Manuela , Schöls, Lüdger , Synofzik, Matthis , Hübener‐Schmid, Jeannette , Puschmann, Andreas , Gorcenco, Sorina , Petrucelli, Leonard , Jansen-West, Karen R , Hanna Al-Shaikh, Rana , Pereira de Almeida, Luis , Infante, Jon , Reetz, Kathrin , Raposo, Mafalda , Lima, Manuela , Schöls, Ludger , Synofzik, Matthis , Hübener-Schmid, Jeannette , Puschmann, Andreas , Gorcenco, Sorina , Wszolek, Z.K. , Petrucelli, Leonard , Giunti, Paola , Prudencio, Mercedes , Zetterberg, Henrik , Januário, Cristina , Wszołek, Zbigniew K.

Mayo Clinic

European Journal of Neurology | April 28, 2022 | Volume: 29 | Issue: 8 | Pages: 2439-2452

10.1111/ene.15373 | PMID 35478426 Get It

AbstractBackground and purposeClinical trials in spinocerebellar ataxia type 3 (SCA3) will require biomarkers for use as outcome measures.MethodsTo evaluate total tau (t‐tau), glial fibrillary acidic protein (GFAP), ubiquitin carboxy‐terminal hydrolase L1 (UCHL1) and neurofilament light‐chain (NfL) as fluid biomarkers in SCA3, ATXN3 mutation carriers (n = 143) and controls (n = 172) were clinically assessed, and the plasma concentrations of the four proteins were analysed on the Simoa HD‐1 platform. Eleven ATXN3 mutation carrier cerebrospinal fluid samples were analysed for t‐tau and phosphorylated tau (p‐tau181). A transgenic SCA3 mouse model (MJDTg) was used to measure cerebellar t‐tau levels.ResultsPlasma t‐tau levels were higher in mutation carriers below the age of 50 compared to controls, and the Inventory of Non‐Ataxia Signs was associated with t‐tau in ataxic patients (p = 0.004). Pre‐ataxic carriers showed higher cerebrospinal fluid t‐tau and p‐tau181 concentrations compared to ataxic patients (p = 0.025 and p = 0.014, respectively). Cerebellar t‐tau was elevated in MJDTg mice compared to wild‐type (p = 0.033) only in the early stages of the disease. GFAP and UCHL1 did not show higher levels in mutation carriers compared to controls. Plasma NfL concentrations were higher in mutation carriers compared to controls, and differences were greater for younger carriers. The Scale for the Assessment and Rating of Ataxia was the strongest predictor of NfL in ataxic patients (p < 0.001).ConclusionOur results suggest that tau might be a marker of early disease stages in SCA3. NfL can discriminate mutation carriers from controls and is associated with different clinical variables. Longitudinal studies are required to confirm their potential role as biomarkers in clinical trials.
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
He, Zhijian , Deva, Sanjeev , Hung, Tak, Clarke, Katriona, Chao, Tsu‐Yi , Dai, Ming‐Shen , Yeh, Hsien‐Tang , Kramer, Douglas, Kwan, Rudolf, Cutler, David L. , Zhi, Jay, Jackson, Christopher , Segelov, Eva , Wee, Wen , Chan, Wing‐Kai

Mayo Clinic

CPT: Pharmacometrics & Systems Pharmacology | April 26, 2022 | Volume: 11 | Issue: 7 | Pages: 867-879

10.1002/psp4.12799 | PMID 35470967 Get It

AbstractOraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers that would otherwise be treated with intravenous paclitaxel. Here we describe the population pharmacokinetics (popPK) analyses for oral paclitaxel in patients with advanced/metastatic solid tumors to characterize pharmacokinetic (PK) profiles and quantify sources of PK variability. The best fit popPK model for oral paclitaxel, based on data from seven clinical studies (197 patients with advanced/metastatic solid tumors), involves a linear two‐compartment structural model containing first‐order absorption with a short lag time and first‐order elimination as well as a log additive error. In this popPK model, lower population estimates of central volume for Asian patients versus Caucasian patients did not translate into clinical meaningful differences in oral paclitaxel exposure. Age, sex, body weight or surface area, mild hepatic impairment, and mild to moderate renal impairment had no clinically meaningful effects on the systemic exposure of oral paclitaxel. Simulations were performed on clinical therapeutic dose (oral paclitaxel 205 mg/m2 once daily ×3 days per week) to predict exposure of oral paclitaxel and to support treatment benefits observed in a pivotal phase III trial.